Combination therapy for Gram-negative bacteria: what is the evidence?

References

• Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit. Care Med. 38(8), 1651–1664 (2010).
   PubMed Web of Science ®Google Scholar
• American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171(4), 388–416 (2005).
   PubMed Web of Science ®Google Scholar
• Peterson LR. Bad bugs, no drugs: no ESCAPE revisited. Clin. Infect. Dis. 49(6), 992–993 (2009).
   PubMed Web of Science ®Google Scholar
• Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J. Infect. Dis. 197(8), 1079–1081 (2008).
   PubMed Web of Science ®Google Scholar
• Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am. J. Med. 87(5), 540–546 (1989).
   PubMed Web of Science ®Google Scholar
• Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect. Dis. 4(8), 519–527 (2004).
   PubMed Web of Science ®Google Scholar
• Park SY, Park HJ, Moon SM et al. Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia. BMC Infect. Dis. 12, 308 (2012).
   PubMed Web of Science ®Google Scholar
• Chamot E, Boffi El Amari E, Rohner P, Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 47(9), 2756–2764 (2003).
   PubMed Web of Science ®Google Scholar
• Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 328(7441), 668 (2004).
   Google Scholar
• Bowers DR, Liew YX, Lye DC, Kwa AL, Hsu LY, Tam VH. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 57(3), 1270–1274 (2013).
   PubMed Web of Science ®Google Scholar
• Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin. Proc. 86(3), 250–259 (2011).
   PubMed Web of Science ®Google Scholar
• Zuravleff JJ, Yu VL, Yee RB. Ticarcillin-tobramycin-rifampin: in vitro synergy of the triplet combination against Pseudomonas aeruginosa. J. Lab. Clin. Med. 101(6), 896–902 (1983).
   PubMed Web of Science ®Google Scholar
• Dundar D, Otkun M. In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains. Yonsei Med. J. 51(1), 111–116 (2010).
   PubMed Web of Science ®Google Scholar
• Dubois V, Arpin C, Melon M et al. Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance. J. Clin. Microbiol. 39(6), 2072–2078 (2001).
   PubMed Web of Science ®Google Scholar
• Fish DN, Choi MK, Jung R. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J. Antimicrob. Chemother. 50(6), 1045–1049 (2002).
   PubMed Web of Science ®Google Scholar
• Urena MT, Barasoain I, Espinosa M, Garcia E, Portoles A. Evaluation of different antibiotic actions combined with rifampicin. In vitro synergism against Pseudomonas and Proteus. Chemotherapy 21(2), 82–89 (1975).
   PubMed Web of Science ®Google Scholar
• Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int. J. Antimicrob. Agents 27(3), 224–228 (2006).
   PubMed Web of Science ®Google Scholar
• Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 47(3), 905–909 (2003).
   PubMed Web of Science ®Google Scholar
• Lim TP, Lee W, Tan TY et al. Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B. PLoS ONE 6(12), e28177 (2011).
   PubMed Web of Science ®Google Scholar
• Korvick JA, Peacock JE Jr, Muder RR, Wheeler RR, Yu VL. Addition of rifampin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: prospective trial using the Zelen protocol. Antimicrob. Agents Chemother. 36(3), 620–625 (1992).
   PubMed Web of Science ®Google Scholar
• Saiman L, Chen Y, Gabriel PS, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother. 46(4), 1105–1107 (2002).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int. J. Antimicrob. Agents 34(2), 111–120 (2009).
   PubMed Web of Science ®Google Scholar
• Yigit H, Queenan AM, Anderson GJ et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 45(4), 1151–1161 (2001).
   PubMed Web of Science ®Google Scholar
• Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg. Infect. Dis. 17(10), 1791–1798 (2011).
   PubMed Web of Science ®Google Scholar
• Pournaras S, Vrioni G, Neou E et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int. J. Antimicrob. Agents 37(3), 244–247 (2011).
   PubMed Web of Science ®Google Scholar
• Souli M, Rekatsina PD, Chryssouli Z, Galani I, Giamarellou H, Kanellakopoulou K. Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates? Antimicrob. Agents Chemother. 53(5), 2133–2135 (2009).
   PubMed Web of Science ®Google Scholar
• Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 55(6), 3002–3004 (2011).
   PubMed Web of Science ®Google Scholar
• Ceccarelli G, Falcone M, Giordano A et al. Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 57(6), 2900–2901 (2013).
   PubMed Web of Science ®Google Scholar
• Giamarellou H, Galani L, Baziaka F, Karaiskos I. Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae. Antimicrob. Agents Chemother. 57(5), 2388–2390 (2013).
   PubMed Web of Science ®Google Scholar
• Souli M, Galani I, Boukovalas S et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob. Agents Chemother. 55(5), 2395–2397 (2011).
   PubMed Web of Science ®Google Scholar
• Qureshi ZA, Paterson DL, Potoski BA et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob. Agents Chemother. 56(4), 2108–2113 (2012).
   PubMed Web of Science ®Google Scholar
• Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin. Microbiol. Rev. 25(4), 682–707 (2012).
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Viale P, Viscoli C et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin. Infect. Dis. 55(7), 943–950 (2012).
   PubMed Web of Science ®Google Scholar
• Daikos GL, Petrikkos P, Psichogiou M et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob. Agents Chemother. 53(5), 1868–1873 (2009).
   PubMed Web of Science ®Google Scholar
• Zarkotou O, Pournaras S, Tselioti P et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin. Microbiol. Infect. 17(12), 1798–1803 (2011).
   PubMed Web of Science ®Google Scholar
• Lim SK, Lee SO, Choi SH et al. The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections. J. Korean Med. Sci. 26(3), 325–331 (2011).
   PubMed Web of Science ®Google Scholar
• Song JY, Kee SY, Hwang IS et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 60(2), 317–322 (2007).
   PubMed Web of Science ®Google Scholar
• Lee NY, Wang CL, Chuang YC et al. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study. Pharmacotherapy 27(11), 1506–1511 (2007).
   PubMed Web of Science ®Google Scholar
• Kuo LC, Lai CC, Liao CH et al. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin. Microbiol. Infect. 13(2), 196–198 (2007).
   PubMed Web of Science ®Google Scholar
• Montero A, Ariza J, Corbella X et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J. Antimicrob. Chemother. 54(6), 1085–1091 (2004).
   PubMed Web of Science ®Google Scholar
• Bernabeu-Wittel M, Pichardo C, Garcia-Curiel A et al. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clin. Microbiol. Infect. 11(4), 319–325 (2005).
   PubMed Web of Science ®Google Scholar
• Saballs M, Pujol M, Tubau F et al. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J. Antimicrob. Chemother. 58(3), 697–700 (2006).
   PubMed Web of Science ®Google Scholar
• Tripodi MF, Durante-Mangoni E, Fortunato R, Utili R, Zarrilli R. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int. J. Antimicrob. Agents 30(6), 537–540 (2007).
   PubMed Web of Science ®Google Scholar
• Sader HS, Rhomberg PR, Jones RN. In vitro activity of beta-lactam antimicrobial agents in combination with aztreonam tested against metallo-beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter baumannii. J. Chemother. 17(6), 622–627 (2005).
   PubMed Web of Science ®Google Scholar
• Scheetz MH, Qi C, Warren JR et al. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51(5), 1621–1626 (2007).
   PubMed Web of Science ®Google Scholar
• Guner R, Hasanoglu I, Keske S, Kalem AK, Tasyaran MA. Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy. Infection 39(6), 515–518 (2011).
   PubMed Web of Science ®Google Scholar
• Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int. J. Antimicrob. Agents 34(1), 8 e1–9 (2009).
   Web of Science ®Google Scholar
• Dizbay M, Tozlu DK, Cirak MY, Isik Y, Ozdemir K, Arman D. In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii. J. Antibiot. 63(2), 51–53 (2010).
   PubMed Web of Science ®Google Scholar
• Sheng WH, Wang JT, Li SY et al. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn. Microbiol. Infect. Dis. 70(3), 380–386 (2011).
   PubMed Web of Science ®Google Scholar
• Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J. Antimicrob. Chemother. 67(7), 1607–1615 (2012).
   PubMed Web of Science ®Google Scholar
• Liang W, Liu XF, Huang J, Zhu DM, Li J, Zhang J. Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients. BMC Infect. Dis. 11, 109 (2011).
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Karnesis L, Giamarellou H. Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn. Microbiol. Infect. Dis. 44(3), 259–263 (2002).
   PubMed Web of Science ®Google Scholar
• Gulmez D, Cakar A, Sener B, Karakaya J, Hascelik G. Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing. J. Infect. Chemother. 16(5), 322–328 (2010).
   PubMed Web of Science ®Google Scholar
• Looney WJ, Narita M, Muhlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect. Dis. 9(5), 312–323 (2009).
   PubMed Web of Science ®Google Scholar
• Munoz JL, Garcia MI, Munoz S, Leal S, Fajardo M, Garcia-Rodriguez JA. Activity of trimethoprim/sulfamethoxazole plus polymyxin B against multiresistant Stenotrophomonas maltophilia. Eur. J. Clin. Microbiol. Infect. Dis. 15(11), 879–882 (1996).
   PubMed Web of Science ®Google Scholar
• San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 48(1), 168–171 (2004).
   PubMed Web of Science ®Google Scholar
• Zelenitsky SA, Iacovides H, Ariano RE, Harding GK. Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia. Diagn. Microbiol. Infect. Dis. 51(1), 39–43 (2005).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Valkimadi PE, Huang YT, Matthaiou DK, Hsueh PR. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J. Antimicrob. Chemother. 62(5), 889–894 (2008).
   PubMed Web of Science ®Google Scholar
• Abbott IJ, Slavin MA, Turnidge JD, Thursky KA, Worth LJ. Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment. Expert Rev. Anti Infect. Ther. 9(4), 471–488 (2011).
   PubMed Web of Science ®Google Scholar
• Chung HS, Hong SG, Kim YR et al. Antimicrobial susceptibility of stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates. J. Korean Med. Sci. 28(1), 62–66 (2013).
   PubMed Web of Science ®Google Scholar
• Wood GC, Underwood EL, Croce MA, Swanson JM, Fabian TC. Treatment of recurrent Stenotrophomonas maltophilia ventilator-associated pneumonia with doxycycline and aerosolized colistin. Ann. Pharmacother. 44(10), 1665–1668 (2010).
   PubMed Web of Science ®Google Scholar